Results 31 to 40 of about 68,603 (270)
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs.
Simone C. Oostindie +16 more
doaj +1 more source
Lamprey Variable Lymphocyte Receptors Mediate Complement-Dependent Cytotoxicity [PDF]
Abstract An alternative adaptive-immune system is present in the most basal vertebrates—lampreys and hagfish—the only surviving jawless vertebrates. These eel-like fish use leucine-rich repeat–based receptors for Ag recognition instead of the Ig-based receptors used in jawed vertebrates.
Fenfang, Wu +12 more
openaire +2 more sources
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer +7 more
doaj +1 more source
Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity [PDF]
In the human placenta, extravillous trophoblasts (EVTs) invade maternal decidual tissues (interstitial trophoblasts) and maternal spiral arteries (endovascular trophoblasts). Although endovascular trophoblasts are directly exposed to maternal blood containing complement components, they are not eliminated by complement-dependent cytotoxicity (CDC).
Masashi Ueda +9 more
openaire +2 more sources
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross +10 more
doaj +1 more source
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. [PDF]
Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement ...
Mark T Winkler +7 more
doaj +1 more source
Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. [PDF]
Studies of neuromyelitis optica (NMO), an autoimmune disease of the central nervous system (CNS), have demonstrated that autoantibodies against the water channel aquaporin-4 (AQP4) induce astrocyte damage through complement-dependent cytotoxicity (CDC).
Liu Y +5 more
europepmc +3 more sources
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath +2 more
doaj +1 more source
The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be ...
Josée Golay, Ronald P. Taylor
doaj +1 more source

